Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial

In SOLO1, maintenance olaparib (300 mg twice daily) significantly improved progression-free survival (PFS) for patients with newly diagnosed BRCA1- and/or BRCA2-mutated advanced ovarian cancer compared with placebo (hazard ratio [HR], 0.30; 95% CI, 0.23 to 0.41; median not reached v 13.8 months). We...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: DiSilvestro, Paul, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S., Gourley, Charlie, Banerjee, Susana, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol A., Bradley, William H., Mathews, Cara A., Liu, Joyce, Lowe, Elizabeth S., Bloomfield, Ralph, Moore, Kathleen N.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8190876/
https://ncbi.nlm.nih.gov/pubmed/32749942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00799
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares